Literature DB >> 16533707

Chromatin control and cancer-drug discovery: realizing the promise.

Adam G Inche1, Nicholas B La Thangue.   

Abstract

Recent years have seen major advances in elucidating the complexity of chromatin and its role as an epigenetic regulator of gene expression in eukaryotes. We now have a basic understanding of chromatin control and the enzymatic modifications that impart diverse regulatory cues to the functional activity of the genome. Most importantly, although research into chromatin has uncovered fascinating insights into the control of gene expression, it has also generated a large body of information that is being harnessed to develop new therapeutic modalities for treating cancer. Here, we discuss recent advances that support the contention that future generations of chromatin-modulating drugs will provide a significant group of new, mechanism-based therapeutics for cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16533707     DOI: 10.1016/S1359-6446(05)03691-3

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  17 in total

Review 1.  Histone deacetylases as targets for treatment of multiple diseases.

Authors:  Jinhua Tang; Haidong Yan; Shougang Zhuang
Journal:  Clin Sci (Lond)       Date:  2013-06       Impact factor: 6.124

2.  Abnormal histone acetylation of CD8+ T cells in patients with severe aplastic anemia.

Authors:  Weiwei Qi; Li Yan; Chunyan Liu; Rong Fu; Huaquan Wang; Zonghong Shao
Journal:  Int J Hematol       Date:  2016-08-02       Impact factor: 2.490

Review 3.  HDAC inhibitor-based therapies: can we interpret the code?

Authors:  Maria New; Heidi Olzscha; Nicholas B La Thangue
Journal:  Mol Oncol       Date:  2012-10-23       Impact factor: 6.603

Review 4.  New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.

Authors:  Michele Cea; Antonia Cagnetta; Marco Gobbi; Franco Patrone; Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 5.  Epigenetics in acute kidney injury.

Authors:  Jinhua Tang; Shougang Zhuang
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-07       Impact factor: 2.894

Review 6.  Connections between epigenetic gene silencing and human disease.

Authors:  Timothy J Moss; Lori L Wallrath
Journal:  Mutat Res       Date:  2007-01-21       Impact factor: 2.433

7.  HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy.

Authors:  Omar Khan; Susan Fotheringham; Victoria Wood; Lindsay Stimson; Chunlei Zhang; Francesco Pezzella; Madeleine Duvic; David J Kerr; Nicholas B La Thangue
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

Review 8.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

9.  A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors.

Authors:  M New; H Olzscha; G Liu; O Khan; L Stimson; J McGouran; D Kerr; A Coutts; B Kessler; M Middleton; N B La Thangue
Journal:  Cell Death Differ       Date:  2013-05-24       Impact factor: 15.828

10.  Class IIa HDAC inhibitor TMP195 alleviates lipopolysaccharide-induced acute kidney injury.

Authors:  Wei Zhang; Yinjie Guan; George Bayliss; Shougang Zhuang
Journal:  Am J Physiol Renal Physiol       Date:  2020-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.